Table 2 |
|||||
|
Changes over time in the expression of cell surface antigens (p < 0.05) on PBMC from HIV+ individuals treated with highly active antiretroviral therapy |
|||||
| Antigen |
Baseline |
TimePoint2 |
TimePoint3 |
TimePoint4 |
P valuea |
|
|
|||||
| CD2 |
124 (103–147) |
126 (107–156) |
130 (84–136) |
144 (129–163) |
0.047 |
| CD3 |
70 (59–86) |
70 (52–90) |
69 (43–85) |
94 (85–117) |
0.007 |
| CD5 |
90 (76–120) |
89 (76–129) |
88 (75–106) |
121 (98–137) |
0.040 |
| CD36 |
44 (29–63) |
43 (34–56) |
61 (40–77) |
62 (45–75) |
0.017 |
| CD95 |
101 (89–115) |
100 (95–121) |
99 (95–121) |
121 (97–131) |
0.032 |
| CD27 |
30 (19–40) |
37 (18–60) |
20 (11–57) |
47 (35–72) |
0.015 |
| CD28 |
61 (33–81) |
81 (55–92) |
65 (47–80) |
81 (71–95) |
0.007 |
|
|
|||||
|
Data are presented as median dot intensities (i.e., cell binding densities) quantified using DotScan data analysis software on an 8-bit pixel grey scale from 0–255. The 25th–75th quartile values are shown in brackets. The cut off value of 10 was used for the detectable expression levels. a Level of significance of the time parameter in a repeated measure mixed model analysis of variance was used to assess the changes in cell binding density values over time. |
|||||
|
Wu et al. Retrovirology 2008 5:24 doi:10.1186/1742-4690-5-24 |
|||||
